Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155042 | 1.00 | RXFP1 (0.51) | RXFP1MAOBKMT2AALDH1A1HSD17B10 | |
| SCHEMBL19969451 | 0.92 | RXFP1 (0.57) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| SCHEMBL19969448 | 0.91 | RXFP1 (0.59) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| SCHEMBL11826620 | 0.88 | RXFP1 (0.56) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| SCHEMBL19969307 | 0.85 | RXFP1 (0.51) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| SCHEMBL26439807 | 0.85 | RXFP1 (0.51) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| SCHEMBL19969447 | 0.84 | RXFP1 (0.62) | RXFP1MAOBKMT2AMAOACYP2C19 | |
| Choline SCHEMBL29026617 | 0.84 | ALDH1A1 (0.51) | RXFP1MAOBKMT2AALDH1A1HSD17B10 | |
| SCHEMBL15071609 | 0.83 | CYP1A2 (0.56) | RXFP1MAOBKMT2AHSD17B10TP53 | |
| SCHEMBL19969387 | 0.83 | RXFP1 (0.52) | RXFP1MAOBKMT2AMAOACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4087560-A2 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | Axial Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | RXFP1 3236/4885MAOB 553/4885KMT2A 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.